Glucagon is a fundamental regulator of glycemic control, through its ability to stimulate hepatic glucose production, and numerous studies have demonstrated that there is dysregulation of glucagon in all forms of diabetes. Interest in this pancreatic alpha cell hormone has grown considerably in recent years and with advances in the drug development arena, the need to address long-standing analytical obstacles has become even more urgent.
Click here to read the white paper GLUCAGON MEASUREMENT: ADDRESSING LONG-STANDING ANALYTICAL CHALLENGES
Why don’t changes in insulin fully explain changes in glycemic control? How is glucagon affected by therapies currently approved or under investigation? During studies in which a metabolic marker(s) is included, why consider glucagon? Get answers to these questions and understand why Glucagon is an important biomarker for diabetes research.
Click here to read the white paper GLUCAGON: METABOLIC REGULATOR CRITICAL FOR PATHOPHYSIOLOGY AND PHARMACOLOGY
How the introduction of a specific glicentin ELISA made glucagon measurements even more specific –
a fruitful collaboration with academic researchers.
Click here to read the white paper HOW THE INTRODUCTION OF A SPECIFIC GLICENTIN ELISAMADE GLUCAGON MEASUREMENTS EVEN MORE SPECIFIC